Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy acquires Biovel vaccine business

India's largest pharmaceutical company, Ranbaxy, has announced it is to acquire the product rights and manufacturing facility of Biovel Lifesciences

India's largest pharmaceutical company, Ranbaxy, has announced it is to acquire the product rights and manufacturing facility of Biovel Lifesciences. The value of the deal was not disclosed.

The transaction will provide Ranbaxy with access to all of Biovel's products (including the Typhoid Vi antigen and Hib conjugate vaccines, for which Biovel has received regulatory approval for India), intellectual property and its pipeline, along with a manufacturing facility in Bangalore, India.

Ranbaxy's CEO and MD, Atul Sobti, said: "With an increasing focus on prevention of disease, the importance of the vaccine market has never been greater. This transaction with Biovel provides us an entry platform to manufacture vaccines as well as biotherapeutics. The vaccine and biotherapeutics business will be an important part of our growth strategy."

According to Ranbaxy, the Indian vaccine market is growing at 10 per cent per annum – 1 per cent higher than the global rate. The global vaccines market is predicted to reach $34bn by 2014.

20th January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics